Drug-maker GlaxoSmithKline has paid over $150 million to resolve charges that it defrauded Medicare and other federal health programs through fraudulent drug pricing and marketing of two drugs used in cancer care, Zofran and Kytril. A whistleblower in the case will get $26 million.
The government charged that GlaxoSmithKline -- one of the worlds largest pharmaceutical manufacturers -- engaged in a scheme to set and maintain fraudulent and inflated prices for Zofran and Kytril knowing that federal healthcare programs established reimbursement rates based on those prices.
The difference between the reimbursement rate of the federal health care programs and the actual price paid by healthcare providers for a drug is commonly known as the spread. The larger the spread on a drug, the larger the profit or return on investment for the provider.
GlaxoSmithKline allegedly used the spread to market, promote, and sell the drugs to existing and potential customers. Because reimbursement from federal programs was based on the fraudulent, inflated prices, the government contends that GlaxoSmithKline caused false and fraudulent claims to be submitted to federal healthcare programs.
This agreement marks another in a series of cases in which a pharmaceutical manufacturer has settled claims that its fraudulent drug pricing cost federal healthcare programs and taxpayers millions of dollars, said Assistant Attorney General Peter D. Keisler of the Justice Departments Civil Division.
The Justice Department will continue to pursue these types of fraud schemes vigorously to make clear that we will not tolerate fraudulent pricing practices designed to reap profits for drug companies and doctors at the expense of healthcare programs for the poor and the elderly.
The United States also alleged that, with respect to Kytril, the drug company engaged in a double dipping billing scheme by encouraging customers to pool leftover vials of Kytril to create an extra dose, which then would be administered to a patient and re-billed to Medicare and other federal healthcare programs.
Fraudulent pricing of prescription drugs can cost American taxpayers millions of dollars and undermine the financial integrity of the healthcare system, said U.S. Attorney Michael J. Sullivan of the District of Massachusetts.
To safeguard our nations healthcare programs we will continue to aggressively investigate and prosecute healthcare fraud violations whether by pharmaceutical companies or individual practitioners.
The investigation was triggered by the filing of a civil False Claims Act suit by a small, home-infusion company, Ven-A-Care of the Florida Keys, Inc., and its principals. The civil False Claims Act allows for private persons to file whistleblower suits to provide the government information about wrongdoing.
Where persons submit or cause others to submit false or fraudulent claims to the United States, the government is entitled to recover treble damages and $5,500 to $11,000 for each false or fraudulent claim. In cases in which the government is successful in resolving or litigating its claims, the whistleblower may receive a share of the recovery by receiving from 15-25% of the amount recovered. As part of this settlement, the Ven-A-Care whistleblowers will receive a share of approximately $26 million.
As part of a condition for doing business in the future with providers who do business with the Medicare and Medicaid programs, GlaxoSmithKline has agreed to enter into an addendum to its existing Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services that, among other things, will require the company to report accurate average sales prices and average manufacturers prices for its drugs covered by Medicare and other federal healthcare programs.
Any pharmaceutical company that intentionally inflates the cost of prescription drugs with elaborate pricing schemes robs states and beneficiaries nationwide of millions of Medicare and Medicaid dollars. We will not tolerate any company abusing programs intended to benefit our most vulnerable citizens, said Daniel R. Levinson, HHS Inspector General.
